Peter Maslak

MD
Hematologic Oncology

Cancers Treated:

Leukemia

About Peter Maslak

Biography:

I have a long-standing interest in immunologic approaches to cancer therapeutics and have the laboratory as well as clinical background. I recently have joined Roswell Park Comprehensive Cancer Center, where I am the Vice Chair of Clinical Operations, the Director of Flow Cytometry in the Immune Monitoring Shared Resources and the Technical Director of the Flow Cytometry Lab with Pathology and Laboratory Medicine. Prior to this, I was Chief of the Immunology Service in the Department of Laboratory Medicine and an attending physician on the Leukemia Service in the Department of Medicine at Memorial-Sloan Kettering Cancer Center.

I have more than 25 years of experience in clinical flow cytometry and immunophenotyping and have been instrumental in developing laboratory correlates in support of various clinical trials with a particular emphasis on the therapy of leukemia. I managed the activity of a CLIA deemed laboratory which supported all hematopoietic stem cell and cellular therapy at MSKCC. The laboratory was actively involved in monitoring immune reconstitution as well as defining the graft content in the setting of various ex vivo manipulations performed on both peripheral blood and bone marrow. During the recent COVID pandemic, we played a major role in helping to define the immune response immunocompromised cancer patients.

My current research interests also include identifying immunologic targets and the implementation of strategies such as vaccination and cell based therapies to harness the immune system and effect cure.

Positions

Roswell Park Comprehensive Cancer Center
  • Professor of Oncology
  • Vice Chair of Clinical Affairs, Department of Medicine
  • Department of Medicine and Pathology
  • Director, Flow Cytometry/Immune Monitoring Shared Resources Core
  • Technical Director, Roswell Park Clinical Flow Cytometry Laboratory, Department of Pathology and Laboratory Medicine

Background

Education and Training:

  • 1980-1984 - MD - Mt. Sinai School of Medicine City University of New York, New York City, N.Y.
  • 1980 - BS - Biology, Columbia College, New York City, NY

Residency:

  • 1984 - 1987 - Internal medicine, Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor, MI

Fellowship:

  • 1987-1991 - Fellow in Medicine, Weill Cornell Medical College, New York City, NY
  • 1988-1990 - Research Fellow, Laboratory of Leukemia Cell Biology, Memorial Sloan Kettering Cancer Center, New York City, NY
  • 1987 - 1988 - Clinical Fellow, Hematology/Oncology, Memorial Sloan Kettering Cancer Center, New York City, NY

Board Certification:

  • American Board of Internal Medicine
  • American Board of Internal Medicine - Medical Oncology
  • American Board of Internal Medicine - Hematology

Professional Memberships:

  • American Association for Cancer Research
  • American Society of Clinical Oncology
  • American Society of Hematology
  • International Society for Analytical Cytology
  • International Society for Cellular Therapy
  • American Society for Transplantation and Cellular Therapy
  • American College of Physicians
  • Society for Immunotherapy of Cancer
  • Royal Society of Medicine (UK)

Professional Experience:

  • 2022-2023 - Director, Evelyn Lauder Breast Center Clinical Laboratory, Memorial Sloan Kettering Cancer Center, New York City, NY
  • 2015–2023 - Chief, Immunology Laboratory Service, Memorial Hospital, New York City, NY
  • 2008–2023 - Professor of Clinical Medicine, Weill Cornell Medical College, New York City, NY
  • 2007– 2023 - Member, Memorial Hospital, Memorial Sloan Kettering Cancer Center, New York City, NY
  • 2005–2016 - Director, Evelyn Lauder Breast Center Clinical Library, Memorial Sloan Kettering Cancer Center, New York City, NY
  • 2002–2015 - Chief, Hematology Laboratory Service, Memorial Hospital, New York City, NY
  • 2002–2008 - Associate Professor of Clinical Medicine, Weill Cornell Medical College, New York City, NY
  • 2001–2007 - Associate Member, Memorial Hospital, Memorial Sloan Kettering Cancer Center, New York City, NY
  • 1995–2002 - Assistant Professor of Medicine, Weill Cornell Medical College, New York City, NY
  • 1994–2001 - Assistant Member, Memorial Sloan Kettering Cancer Center, New York City, NY
  • 1992–1995 - Instructor in Medicine, Weill Cornell Medical College, New York City, NY
  • 1991–1994 - Clinical Assistant, Memorial Sloan Kettering Cancer Center, New York City, NY

Honors & Awards:

  • 2002 - Hematology Teaching Award, Medical Oncology Fellowship, Memorial Sloan Kettering Cancer Center, New York City, NY
  • 2001 - Hematology Teaching Award, Medical Oncology Fellowship, Memorial Sloan Kettering Cancer Center, New York City, NY
  • 1996 - Hematology Teaching Award, Medical Oncology Fellowship, Memorial Sloan Kettering Cancer Center, New York City, NY
  • 1996 - Paul Sherlock Housestaff Teaching Award, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York City, NY
  • 1995 - Paul Sherlock Housestaff Teaching Award, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York City, NY
  • 1994 - Career Development Award, American Cancer Society
  • 1991 - Hematology Teaching Award, Medical Oncology Fellowship, Memorial Sloan Kettering Cancer Center, New York City, NY
  • 1991 - Paul Sherlock Housestaff Teaching Award, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York City, NY

Featured on Cancer Talk

Meet the Team: Peter Maslak, Director of the Immune Monitoring Resource

Publications

Full Publications list on PubMed

1. Park JH, Riviere I, Gonen M, Wang X, Senechal B, Curran KJ, Sauter C, Wang Y, Santomasso B, Mead E, Roshal M, Maslak P, Davila M, Brentjens RJ, Sadelain M. Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N Engl J Med 2018 Feb1:378(5): 449-459.PMID: 29385376 PMCID: PMC6637939

2. Davila ML, Riviere I, Wang X, Bartido S, Park J, Curran K, Chung SS, Stefanski J, Borquez-Ojeda O, Olszewska M, Qu J, Wasielewska T, He Q, Fink M, Shinglot H, Youssif M, Satter M, Wang Y, Hosey J, Quintanilla H, Halton E, Bernal Y, Bouhassira DC, Arcila ME, Gonen M, Roboz GJ, Maslak P, Douer D, Frattini MG, Giralt S, Sadelain M, Brentjens R. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med. 2014 Feb 19;6(224):224ra25. PubMed PMID: 24553386; PubMed Central PMCID: PMC4684949

3. Brentjens RJ, Davila ML, Riviere I, Park J, Wang X, Cowell LG, Bartido S, Stefanski J, Taylor C, Olszewska M, Borquez-Ojeda O, Qu J, Wasielewska T, He Q, Bernal Y, Rijo IV, Hedvat C, Kobos R, Curran K, Steinherz P, Jurcic J, Rosenblat T, Maslak P, Frattini M, Sadelain M. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med. 2013 Mar 20;5(177):177ra38. PubMed PMID: 23515080; PubMed Central PMCID: PMC3742551.

4. Brentjens RJ, Rivière I, Park JH, Davila ML, Wang X, Stefanski J, Taylor C, Yeh R, Bartido S, Borquez-Ojeda O, Olszewska M, Bernal Y, Pegram H, Przybylowski M, Hollyman D, Usachenko Y, Pirraglia D, Hosey J, Santos E, Halton E, Maslak P, Scheinberg D, Jurcic J, Heaney M, Heller G, Frattini M, Sadelain M. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood. 2011 Nov 3;118(18):4817-28. PubMed PMID: 21849486; PubMed Central PMCID: PMC3208293